Welcome to our dedicated page for Abivax news (Ticker: ABVX), a resource for investors and traders seeking the latest updates and insights on Abivax stock.
Abivax SA reports developments as a clinical-stage biotechnology company developing therapeutics that modulate immune response in chronic inflammatory diseases. Its news centers on obefazimod (ABX464), the company’s lead therapeutic candidate, including clinical and preclinical data in inflammatory bowel disease, Phase 3 ABTECT work in moderately to severely active ulcerative colitis, and related safety, efficacy, biomarker, and patient-reported outcome analyses.
Recurring updates also cover financial results, annual and regulatory reporting in France and the United States, American Depositary Share offerings, royalty certificate obligations, public-company governance, annual meeting materials, and trading references for its Euronext Paris and Nasdaq-listed securities.
Abivax (Nasdaq:ABVX) held its annual general meeting of shareholders on May 11, 2026, chaired by Board Chair Sylvie Grégoire.
Shareholders approved all resolutions proposed by the Board, including 2025 financial statements, executive and director compensation policy, and delegations for financial transactions. Detailed voting results will be posted on Abivax's website.
Abivax (NASDAQ:ABVX) announced repurchase of its Royalty Certificates for $90 million and the simultaneous pricing of a $45 million offering of 403,347 ADSs at $111.57 per ADS on May 5, 2026. The transaction pays $45 million cash at closing and converts the remaining $45 million into ADSs, cancelling the certificates.
The company reports cash, equivalents and short-term investments of €530.4 million as of December 31, 2025, and projects a cash runway into Q4 2027 unchanged after the repurchase.
Abivax (NASDAQ:ABVX) will present nine scientific abstracts on obefazimod at Digestive Disease Week, May 2–5, 2026, highlighting Phase 3 ABTECT efficacy, safety, patient-reported outcomes and preclinical anti-fibrotic models. Presentations include one oral session and multiple posters covering histologic, endoscopic, biomarker, and quality-of-life data.
Abivax (Euronext/Nasdaq: ABVX) will hold its Annual Ordinary and Extraordinary General Meeting on May 11, 2026 at 3:00 pm CEST in Paris (Paris Marriott Opera Ambassador).
Preparatory documents, agenda and draft resolutions are available to shareholders on the company website and were published in BALO on April 3, 2026 (N°2600756).
Abivax (Nasdaq: ABVX / Euronext: FR0012333284) filed its Universal Registration Document with the Autorité des Marchés Financiers and its Annual Report (Form 20-F) with the U.S. SEC. The 20-F filing date was March 23, 2026.
The Universal Registration Document contains the 2025 annual financial report, management and corporate governance reports, and statutory auditors' reports. Documents are available for download on Abivax, AMF, and SEC websites.
Abivax (NASDAQ:ABVX) reported full-year 2025 results and program updates on March 23, 2026. Key highlights include €530.4M cash and short-term investments (runway into Q4 2027), completion of a $700.3M net US offering, and a DSMB safety review reporting no new safety signals for the Phase 3 ABTECT-UC maintenance trial.
The Company remains on track to report topline ABTECT-UC maintenance results in late Q2 2026, appointed a new Chief Commercial Officer, and reported a 2025 net loss of €336.1M.
Abivax (NASDAQ:ABVX) presented 22 abstracts at ECCO 2026 showing first preclinical evidence of anti-fibrotic activity for obefazimod and new clinical efficacy, safety, and biomarker data in inflammatory bowel disease.
Key findings: robust reductions in fibrosis markers (~45–90% in models), early symptomatic response by week 1 and remission by week 2, upregulation of miR-124, lowered IL-17A/IL-6, and comparable serious TEAE rates versus placebo in pooled Phase 3 induction data.
Abivax (NASDAQ:ABVX) provided its 2026 corporate outlook, highlighting progress for obefazimod in ulcerative colitis (UC) and Crohn’s disease (CD), market research projecting worldwide UC sales rising from $9.2B in 2025 to $21.2B by 2032, and DSMB safety review of ABTECT showing no new safety signals with >80% of participants completing the 44-week maintenance phase.
Topline ABTECT-UC maintenance results are expected late Q2 2026 with a planned US filing in late 2026. ENHANCE-CD induction results are expected late 2026. Cash runway is projected into Q4 2027 after full debt repayment in Q4 2025. Twenty-two abstracts will be presented at ECCO Feb 18-21, 2026.
Abivax (Nasdaq: ABVX) will be added to the Nasdaq Biotechnology Index (NBI), effective prior to market open on December 22, 2025. The inclusion follows the company meeting NBI eligibility requirements such as minimum market capitalization, average daily trading volume and public company seasoning.
Company management tied the index inclusion to progress advancing obefazimod, citing successful Phase 3 ABTECT Induction trials for ulcerative colitis. The NBI is reviewed annually in December and uses a modified capitalization-weighted methodology.
Abivax (Nasdaq: ABVX) announced that 22 abstracts on obefazimod in inflammatory bowel disease were accepted for presentation at ECCO 2026 (Feb 18–21, 2026) in Stockholm. The program includes 1 oral presentation (Feb 21) reporting the first preclinical evidence of anti-fibrotic activity, 5 digital oral presentations, and 16 posters detailing subgroup analyses, biomarker changes (IL-17A, IL-6), early symptomatic improvements, and an integrated safety summary from the Phase 3 ABTECT induction trials in moderately to severely active ulcerative colitis.
The oral preclinical data address intestinal fibrosis—an unmet need in Crohn’s disease—using human small-intestinal fibroblasts and a TNBS-colitis mouse model; multiple abstracts report pooled and subgroup clinical results and safety findings from ABTECT-1 and ABTECT-2.